EmailFacebookXLinkedIn

SIOG_HO

About SIOG Head Office

This author has not yet filled in any details.
So far SIOG Head Office has created 425 blog entries.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

2021-07-29T22:37:57+02:00

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U. Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi2021-07-29T22:37:57+02:00

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

2021-07-29T22:37:57+02:00

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P. Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial2021-07-29T22:37:57+02:00

Chirec Cancer Institute (CCI)

2025-06-12T19:29:22+02:00

Program Opportunities Involvement in any clinical activity: Clinical board and outpatient clinics; observership Availability of any funding supporting any trainee/researcher: Not available Duration of program: According to previous agreement, minimum 1 month Application process: Send a CV and letter of interest to the contact person Accepts international trainees: Yes Contact person: lissandra.dallago@chirec.be Website: https://www.chirec.be/fr/centre_parent/chirec-cancer-institute-cci  

Chirec Cancer Institute (CCI)2025-06-12T19:29:22+02:00

Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force

2021-07-29T22:37:57+02:00

John O. Prior, Silke Gillessen, Manfred Wirth, William Dale, Matti Aapro, Wim J.G. Oyen. European Journal of Cancer, Volume 77, May 2017

Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force2021-07-29T22:37:57+02:00

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

2021-07-29T22:37:57+02:00

Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F1 Lancet Haematol. 2017 Jan;4(1):e46-e55. doi: 10.1016/S2352-3026(16)30171-5.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group2021-07-29T22:37:57+02:00

Istituto Oncologico del Veneto (IOV)

2021-10-25T15:44:58+02:00

Program Opportunities Geriatric Oncology observership and research opportunities are available at the Istituto Oncologico del Veneto (IOV) in Padova, Italy. Program:​ Observership and Clinical/epidemiologica​l research in geriatric oncology Funding availibility: ​None as of now Duration of program: ​6-12 months Application process: Send email to contact person Accept international trainees: yes Contact person: ​Antonella Brunello, antonella.brunello@iov.veneto.it; tel. +39 0498215953 ​W​ebsite​

Istituto Oncologico del Veneto (IOV)2021-10-25T15:44:58+02:00

Hospital Universitario Rey Juan Carlos

2021-07-29T22:37:58+02:00

Program Opportunities Program: Observership Funding availibility: No Duration of program: TBD Application process: Contact Dr Martinez-Peromingo Accept international trainees: yes Contact person: Javier Martinez-Peromingo javier.mperomingo@hospitalreyjuancarlos.com Website: http://www.hospitalreyjuancarlos.com

Hospital Universitario Rey Juan Carlos2021-07-29T22:37:58+02:00

Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study

2021-07-29T22:37:58+02:00

Ferrat E, Paillaud E, Caillet P, Laurent M, Tournigand C, Lagrange JL, Droz JP, Balducci L, Audureau E, Canouï-Poitrine F, Bastuji-Garin S. J Clin Oncol. 2017 Mar;35(7):766-777. doi: 10.1200/JCO.2016.69.3143. Epub 2017 Jan 17.

Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study2021-07-29T22:37:58+02:00

Stay in touch and share our news!

SIOG Head Office

  • International Society of Geriatric Oncology
    P/A Comptabilis
    9 route des Jeunes
    1227 Les Acacias - Switzerland

  • +49 30 24603-152
  • enquiry@siog.org

ECOSOC Special

In Special Consultative Status with the United Nations Economic and Social Council (ECOSOC).

Quick links

 

Stay in the loop with SIOG’s newsletter!

Subscribe now

Powered by K.I.T. Group – Crafted for Excellence

Go to Top